(Q55467147)

12 July 2018

title

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. (English)

1 reference

12 July 2018

main subject

phase I clinical trial

0 references

0 references

1 reference

5

1 reference

12 July 2018

J Gregory Cairncross

7

object named as

Gregory Cairncross

1 reference

12 July 2018

author name string

Peter Forsyth

1

1 reference

12 July 2018

Gloria Roldán

2

1 reference

12 July 2018

David George

3

1 reference

12 July 2018

Carla Wallace

4

1 reference

12 July 2018

Don Morris

6

1 reference

12 July 2018

Maureen Vallee Matthews

8

1 reference

12 July 2018

James Markert

9

1 reference

12 July 2018

Yancey Gillespie

10

1 reference

12 July 2018

Matt Coffey

11

1 reference

12 July 2018

Brad Thompson

12

1 reference

12 July 2018

Mark Hamilton

13

1 reference

12 July 2018

publication date

5 February 2008

1 reference

12 July 2018

published in

Molecular Therapy

1 reference

12 July 2018

volume

16

1 reference

12 July 2018

page(s)

627-632

1 reference

12 July 2018

issue

3

1 reference

12 July 2018

Recent progress in the battle between oncolytic viruses and tumours

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

MTH-68/H oncolytic viral treatment in human high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Reovirus therapy of tumors with activated Ras pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Proteolytic disassembly is a critical determinant for reovirus oncolysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Reovirus as an oncolytic agent against experimental human malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Viral oncolysis by herpes simplex virus and other viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300403

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300403

1 reference

12 July 2018

release_oddimrmc6fgitddnhr3tmebrwy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oddimrmc6fgitddnhr3tmebrwy

24 November 2022

mapped directly with Wikidata item

PubMed ID

18253152

1 reference

12 July 2018